Lifecore Biomedical Inc

Lifecore Biomedical Inc, our under-utilized fill-finish Contract Drug Manufacturing Organization, continues to win new business at an impressive rate, and the market continues to not care. I continue to believe that when the new business wins translate into revenue the operating leverage will be massive, and Lifecore will generate significant cash. Of note, following the end of the quarter the company issued an 8K noting that holders of Series A Preferred Stock were redeeming their shares, and also that the company is evaluating strategic alternatives. I think that a sale of the company is likely in the not-too-distant future.

Lifecore (LFCR) is positioned to benefit from its ability to sell excess manufacturing capacity, having announced seven new customers in the past nine months, indicating tangible progress under the new CEO and revamped sales team. The lengthy FDA approval processes may delay revenue recognition, but they also create sticky contracts that private investors value more highly. The manager believes that the shares will trade higher or the company will be sold, with insiders owning over 30% of the company, suggesting a potential sale at a substantial premium to the current share price. Growth is expected to return in 2027, particularly as Alcon's contractual minimums begin.

Lifecore Biomedical Inc. (LFCR) continues to win new business at an impressive rate, although the timeline for generating meaningful cash flows has shifted. Despite the market's overreaction to fears of a potential capital raise, the company is well-positioned to manage its capital structure needs. The gap between the public market value of LFCR stock and the private market value of Lifecore’s assets is at an all-time high, suggesting significant upside potential. Management has executed effectively, and there is a belief that private buyers were willing to pay approximately $8 per share three years ago, indicating a strong underlying value.

Lifecore Biomedical Inc. (LFCR) has faced challenges due to shifts at its largest customer and delays in the commercialization of a new product, which have pushed the company's revenue inflection further out than previously expected. These issues have negatively impacted performance, leading to a reduction in our position. The outlook remains uncertain as the company navigates these headwinds.

Lifecore (LFCR) is a contract drug manufacturer currently operating at approximately 20% of capacity. The company has made significant progress in onboarding new customers, which is expected to double its volumes by the end of next year. With a strong CEO and a growing biologics fill-finish market, Lifecore is well-positioned to capitalize on the onshoring of pharmaceutical manufacturing. The company’s improved cost structure and potential for increased EBITDA margins suggest that its current enterprise value of roughly $500 million is modest, with the possibility of 4X+ share price appreciation if capacity is fully utilized.

Lifecore Biomedical Inc is positioned well in the fill-finish CDMO space, with excess capacity to meet a demand that significantly outstrips supply. The company has announced multiple new customer wins, including a GLP-1 and a large international pharmaceutical company, indicating that acquiring additional business is becoming easier. Regulatory changes favor domestic manufacturing, as the FDA has prioritized drugs made in the U.S., and tariffs are being imposed on companies that produce abroad. These factors, combined with high fixed costs and low variable costs, suggest that additional revenue will lead to substantial operating leverage, supporting a bullish outlook.

LifeCore (LFCR) exemplifies a disconnect between share price and business progress. Despite a market reaction to a shelf offering that led to a 10% drop in shares, the company has made significant strides, including customer wins in a late-stage clinical GLP-1 program. Analysts suggest that LFCR could ramp revenues to ~$300M with a 30% Adj. EBITDA margin, indicating substantial upside potential. The manager believes that the current share price does not reflect the company's progress and future opportunities, which are expected to ramp in the second half of 2026.

LifeCore is positioned to significantly increase its revenues and improve margins due to its fully integrated CDMO capabilities. With the new 5 head filler certified in 2024, the company can utilize excess capacity, potentially doubling revenues with minimal capital expenditure. Current EBITDA margins are at 15%, but with operational leverage and cost savings, they are expected to rise to 25%, aligning with industry peers. The market for GLP-1 injectables is expanding, and LifeCore stands to benefit as it can manufacture these drugs, which are currently capacity constrained. If the team can effectively sell this excess capacity, the share price could triple.

Lifecore Biomedical Inc., our fill-finish CDMO, continues to work toward their dual goals of increasing capacity utilization and expanding margins. I continue to believe that achieving these goals is very much a 'when' rather than an 'if.' This belief was founded on global supply and demand dynamics, strengthened by the BIOSECURE Act, and reinforced by the National Security Commission delivering a report and action plan to Congress, which calls for the re-shoring of the biotech supply chain. Considering that building and certifying new fill-finish capacity can take 4 or 5 years, it seems that it would be much easier to partner with a company like Lifecore.

Lifecore Biomedical Inc (LFCR) remains an ugly duckling, but new leadership is making significant progress. The balance sheet has been strengthened, the sales force improved, and new customer wins are being announced. As management continues to execute, capacity utilization will improve, leading to tremendous operating leverage and ultimately free cash flow. A recent filing indicates an 80% chance the business will be sold within the next 3 years, suggesting a potential for higher valuation multiples. If Lifecore were to trade at the same multiple as a recent comparable transaction, shares could be in the low to mid double digits today.